BiotechTube

KB803 + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dystrophic Epidermolysis Bullosa

Conditions

Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa

Trial Timeline

Jun 20, 2025 → Dec 1, 2026

NCT ID
NCT07016750

About KB803 + Placebo

KB803 + Placebo is a phase 3 stage product being developed by Krystal Biotech for Dystrophic Epidermolysis Bullosa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07016750. Target conditions include Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07016750Phase 3Recruiting

Competing Products

4 competing products in Dystrophic Epidermolysis Bullosa

See all competitors
ProductCompanyStageHype Score
Topical beremagene geperpavec + Placebo gelKrystal BiotechPhase 1/2
38
Topical Beremagene GeperpavecKrystal BiotechPhase 3
74
Open Label Topical Beremagene Geperpavec (B-VEC)Krystal BiotechPhase 3
74
LZRSE-Col7A1 Engineered Autologous Epidermal SheetsAbeona TherapeuticsPhase 1/2
33

Other Products from Krystal Biotech

Topical Beremagene GeperpavecPhase 3
74
Open Label Topical Beremagene Geperpavec (B-VEC)Phase 3
74
KB105Phase 2
49
Topical beremagene geperpavec + Placebo gelPhase 1/2
38
KB707 + Opdualag + KEYTRUDA ®( Pembrolizumab)Phase 1/2
38